Hydroxychloroquine

Generic Name: Hydroxychloroquine

Brand Names: Plaquenil, Sovuna

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₂₆ClN_₃O

CAS Number: 118-42-3

Unique Ingredient Identifier: 4QWG6N8QKH

Background: Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like chloroquine. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxychloroquine is also used for the prophylaxis of malaria in regions where chloroquine resistance is unlikely. It was developed during World War II as a derivative of quinacrine with less severe side effects. Chloroquine and hydroxychloroquine are both being investigated for the treatment of SARS-CoV-2.

The FDA emergency use authorization for hydroxychloroquine and chloroquine in the treatment of COVID-19 was revoked on 15 June 2020.

Hydroxychloroquine was granted FDA approval on 18 April 1955.

A recent study reported a fatality in the group being treated with hydroxychloroquine for COVID-19.

Indication: Hydroxychloroquine is indicated for the prophylaxis of malaria where chloroquine resistance is not reported, treatment of uncomplicated malaria (caused by P. falciparum, P. malariae, P. ovale, or P. vivax), chronic discoid lupus erythematosus, systemic lupus erythematosus, acute rheumatoid arthritis, and chronic rheumatoid arthritis.

Associated Conditions: Acute Rheumatoid Arthritis, Malaria, Porphyria Cutanea Tarda, Q Fever, Sjogren's Syndrome (SS), Systemic Lupus Erythematosus, Uncomplicated Malaria caused by Plasmodium Vivax, Uncomplicated Malaria caused by Plasmodium malariae, Uncomplicated Malaria caused by Plasmodium ovale, Chronic Discoid Lupus Erythematosus (DLE), Chronic Rheumatoid Arthritis, Uncomplicated Malaria caused by Plasmodium falciparum

Associated Therapies: -

Clinical Trials

Hydroxychloroquine Efficacy on Behcet's Disease Thrombosis

Not Applicable

Conditions: Behcet's Syndrome, Vascular Type

Interventions: Drug: Hydroxychloroquine

First Posted Date: 2019-07-17

Last Posted Date: 2019-07-25

Lead Sponsor: Assiut University

Target Recruit Count: 50

Registration Number: NCT04022421

Locations: 🇪🇬
Assiut University Hospital, Assiut, Egypt

Acute Rhabdomyolysis and Muscle Pain Associated with Mutations in the LPIN1 Gene - a Retrospective Study Describing the Safety and Efficacy of Hydroxychloroquine Sulfate Given on a Compassionate Basis to Patients Suffering from Lipin-1 Deficiency

Withdrawn

Conditions: LIPIN1 Deficiency

Interventions: Drug: Hydroxychloroquine Sulfate

First Posted Date: 2019-07-05

Last Posted Date: 2024-10-30

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Registration Number: NCT04007562

Locations: 🇫🇷
Hôpital Necker-Enfants Malades, Paris, France

Effect of Bitter in Overweight Female Volunteers

Phase 4

Conditions: Obesity

Interventions: Drug: Placebo
Drug: Hydroxychloroquine sulphate

First Posted Date: 2019-07-02

Last Posted Date: 2019-07-02

Lead Sponsor: Universitaire Ziekenhuizen KU Leuven

Target Recruit Count: 40

Registration Number: NCT04005781

Effect of Hydroxychloroquine Sulphate in Healthy Lean Females

Phase 4

Conditions: Obesity

Interventions: Drug: Placebo
Drug: Hydroxychloroquine Sulphate

First Posted Date: 2019-07-02

Last Posted Date: 2019-07-02

Lead Sponsor: Universitaire Ziekenhuizen KU Leuven

Target Recruit Count: 10

Registration Number: NCT04005768

CPI-613 and Hydroxychloroquine for Patients With High Risk Myelodysplastic Syndrome

Phase 1

Withdrawn

Conditions: Myelodysplastic Syndromes
Progressive Disease

Interventions: Drug: CPI-613
Drug: Hydroxychloroquine

First Posted Date: 2019-04-26

Last Posted Date: 2021-04-14

Lead Sponsor: Wake Forest University Health Sciences

Registration Number: NCT03929211

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States

Hydroxychloroquine Administration for Reduction of Pexophagy

Phase 2

Completed

Conditions: Zellweger Syndrome
Peroxisome Biogenesis Disorders

Interventions: Drug: Placebo
Drug: Hydroxychloroquine

First Posted Date: 2019-02-27

Last Posted Date: 2020-12-17

Lead Sponsor: The Hospital for Sick Children

Target Recruit Count: 3

Registration Number: NCT03856866

Locations: 🇨🇦
The Hospital for Sick Children, Toronto, Ontario, Canada

Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer

Phase 1

Recruiting

Conditions: Stage IV Pancreatic Cancer
Metastatic Pancreatic Carcinoma
Stage II Pancreatic Cancer
Unresectable Pancreatic Carcinoma
Stage IIB Pancreatic Cancer
Stage III Pancreatic Cancer
Stage IIA Pancreatic Cancer

Interventions: Drug: Hydroxychloroquine
Drug: Trametinib

First Posted Date: 2019-01-31

Last Posted Date: 2024-04-19

Lead Sponsor: University of Utah

Target Recruit Count: 39

Registration Number: NCT03825289

Locations: 🇺🇸
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
🇺🇸
University of California, San Francisco, San Francisco, California, United States